The Combination of D-TACE-HAIC, Lenvatinib, and PD-1 Inhibitors Shows Significant Clinical Efficacy in Patients with Unresectable Hepatocellular Carcinoma
Yintao Wu,* Jianyong Zhu,* Hong Zhang, Nianxin Xia Senior Department of Hepato-Pancreato-Biliary Surgery, the First Medical Center of PLA General Hospital, Beijing, 100853, People’s Republic of China*These authors contributed equally to this workCorrespondence: Nianxin Xia, S...
Saved in:
| Main Authors: | Wu Y, Zhu J, Zhang H, Xia N |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-02-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/the-combination-of-d-tace-haic-lenvatinib-and-pd-1-inhibitors-shows-si-peer-reviewed-fulltext-article-CMAR |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparative analysis of efficacy and safety between D-TACE + HAIC + lenvatinib and D-TACE + lenvatinib in the treatment of unresectable massive hepatocellular carcinoma
by: Haohao Lu, et al.
Published: (2024-11-01) -
RALOX-HAIC (raltitrexed + oxaliplatin) combined with lenvatinib improves survival and safety in elderly patients with unresectable hepatocellular carcinoma
by: Haohao Lu, et al.
Published: (2025-05-01) -
Efficacy Analysis of TACE Combined with Lenvatinib and PD-1 Inhibitors in the Treatment of Hepatitis B Virus-Related Unresectable Hepatocellular Carcinoma
by: Yu J, et al.
Published: (2025-07-01) -
Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging
by: Weihao Zhang, et al.
Published: (2025-06-01) -
Efficacy and safety of D-TACE followed by D-RFA for unresectable large hepatocellular carcinoma
by: Qingqing Pang, et al.
Published: (2025-07-01)